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ABSTRACT
HIV infection and undernutrition remain significant public health concerns for infants and children. In infants and children under these conditions,
undernutrition is one of the leading causes of death. Proper management of nutrition and related nutrition complications in these groups
with increased nutrition needs are prominent challenges, particularly in HIV-prevalent poor-resource environments. Several studies support the
complexity of the relation between HIV infection, nutrition, and the immune system. These elements interact and create a vicious circle of poor
health outcomes. Recent studies on the use of probiotics as a novel approach to manage microbiome imbalance and gut-mucosal impairment
in HIV infection are gaining attention. This new strategy could help to manage dysbiosis and gut-mucosal impairment by reducing immune
activation, thereby potentially forestalling unwanted health outcomes in children with HIV. However, existing trials on HIV-infected children are still
insufficient. There are also conflicting reports on the dosage and effectiveness of single or multiple micronutrient supplementation in the survival
of HIV-infected children with severe acute malnutrition. The WHO has published guidelines that include time of initiation of antiretroviral therapy
for HIV-pregnant mothers and their HIV-exposed or HIV-infected children, micronutrient supplementation, dietary formulations, prevention, and
management of HIV therapy. However, such guidelines need to be reviewed owing to recent advances in the field of nutrition. There is a need for new
intervention studies, practical strategies, and evidence-based guidelines to reduce the disease burden, improve adherence to treatment regimen,
and enhance the nutrition, health, and well-being of HIV-infected infants and children. This review provides up-to-date scientific information on
current knowledge and existing challenges for nutrition therapy in HIV-infected infants and children. Moreover, it presents new research findings
that could be incorporated into current guidelines. Adv Nutr 2021;00:1–14.
Keywords: HIV, nutrition, HIV-infected infants and children, current HIV-knowledge in infants, nutritional management of HIV infected children,
WHO HIV management guidelines
Introduction
Since the earliest confirmation of first known cases of infec-
tion with HIV in 1959, the prevalence of children infected
with HIV has grown dramatically due to an increase in the
number of HIV-infected women of childbearing age (1).
Globally, as at 2019, there were about 38 million people
living with HIV, of which aproximatelly 1.8 million were
children aged <14 y (2). During the same period, the number
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of new infections across all ages was around 1.7 million
people, including about 150,000 children aged <14 y (2).
As at the end of june 2020, an estimated 26 million people
had access to antiretroviral therapy (ART), but available data
showed that only 54% of children aged <15 y were receiving
lifelong ART in 2019 (2).
The transmission of HIV from an HIV-positive mother to
her child during pregnancy, labor, delivery, or breastfeeding
is called mother-to-child transmission (MTCT) (3). MTCT
is a significant contributor to the HIV pandemic, accounting
for 9% of new infections globally (4). In the absence of any in-
tervention, the transmission rate ranges from 15% to 45% (3).
Early testing and treatment are crucial to reduce HIV-
related mortality and morbidity among infants. In their
absence, 50% of children with HIV will die by the age
of 2 y, and 80% will not live to their 5th birthday (5).
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Failure to suppress HIV remains a serious problem among
children, aggravated by a lack of child-friendly formulations
of the newest and most effective antiretroviral (ARV) drugs
originally designed for adults (6).
Adequate child nutrition is best achieved through the con-
sumption of a balanced healthy diet. It is essential for normal
growth and development and vital for health and survival for
all individuals regardless of HIV status (7). Infants deserve
unique attention because of increased nutrient needs. Thus,
adequate nutrition of HIV-infected infants becomes critically
important to prevent undernutrition, particularly because of
their nutritional needs and dependency on adults for their
care (8). This has been illustrated by studies that have shown
a high prevalence of undernutrition among HIV-infected
children (9–12).
According to the WHO, dietary interventions for HIV-
infected children should focus on issues of food security,
particularly in terms of quantity and quality of the diet (8).
However, attainment of food security, nutrition accessibility,
and appropriate handling of nutrition-related complications
of HIV infection are remarkably challenging, especially in
poor environments with limited resources where most HIV
infections exist (13). Undernutrition, as presented here, is a
form of malnutrition, which refers to both undernutrition
caused by deficiencies of energy and/or micronutrients and
overnutrition due to excessive energy intake that leads to
overweight and obesity. Undernutrition can be manifested
according to its intensity in stunting, underweight, and wast-
ing, commonly accompanied by micronutrient deficiencies
(13). Severe acute malnutrition (SAM), is the most extreme
and visible form of undernutrition characterized, in children
aged <60 mo, by extreme wasting and weight-for-height z-
score (WHZ) below –3 SDs of the median WHO growth
standards (14). SAM is common in HIV-infected children
(15–17). Given the additional challenges facing HIV-infected
infants and older children, such as opportunistic infections,
growth faltering, and nutritional deficiencies, it is essential
to review new information on the optimal feeding regimens
for HIV-infected children with SAM. Furthermore, it is also
essential to elucidate the most effective strategies for treating
HIV-infected children accompanied by acute or persistent
diarrhea. To address these issues, a series of guidelines have
been developed by the WHO (8) and professional bodies (18,
19). However, different countries have reported challenges in
adhering to such guidelines. The objective of this narrative
review is to provide up-to-date scientific information on
current knowledge of nutrition in HIV-infected infants
and children and explore new scientific evidence that
could be incorporated into current nutrition management
guidelines.
Current Status of Knowledge
Malnutrition and the immune system in HIV-infected
infants
In low- and middle-income countries, about half of all deaths
in children aged under 5 y are linked to undernutrition (20).
Undernutrition puts children at a higher risk of dying from
common infections. It increases the frequency and severity
of infections such as tuberculosis, oral and esophageal can-
didiasis, pneumonia, skin infections, and persistent diarrhea
(PD), resulting in delayed HIV recovery (20–22). Several
studies have shown a high prevalence of undernutrition in
HIV-infected children, especially in sub-Saharan Africa (23–
27). The co-occurrence of the 2 conditions is interlaced
in a vicious cycle of worsening illness and deteriorating
nutritional status (20).
Immunological variations such as systemic inflamma-
tion, increased proinflammatory mediator concentrations,
and impaired cellular immune responses are attributed to
malnutrition (28). This leads to increased susceptibility to
infections, especially when worsened by HIV. HIV gradually
weakens a patient’s immune system by attacking CD4 T-
cells, resulting in the development of opportunistic infections
(29). Undernutrition is also characterized by functional and
structural alterations in the intestinal mucosa, which is
associated with chronic intestinal inflammation (22). The
impact of undernutrition (30, 31) and dysbiosis in the gut
microbiome (32) has been hypothesized as a primary cause
for persistent intestinal inflammation and epithelial damage.
In HIV infection, the breakdown of the intestinal barrier,
depletion of gut-resident CD4+ T-cell populations, and
mucosal immune dysregulation result in microbial translo-
cation that drives systemic immune activation (33). In a
study by Muenchhoff et al. (17), malnutrition, age, microbial
translocation, monocyte, and CD8 T-cell activation were
independently associated with decreased rates of CD4+ im-
mune recovery after 48 wk of ART. SAM has been associated
with increased microbial translocation, immune activation,
and immune exhaustion in HIV-uninfected children, but
with worse prognosis and impaired immune recovery in
HIV-infected children on ART.
Anemia, a likely consequence of micronutrient deficien-
cies, like iron, folate, and vitamin B-12, is also a common
hematological complication of undernutrition and HIV in-
fection (34–36). This condition may result in growth impair-
ment of children (37). Furthermore, coexistence commonly
occurs between iron deficiency and HIV infection (38). In
HIV infection, ferritin, a marker of iron deficiency, may be
altered by inflammation (39, 40). This has been confirmed
by the study of Frosch et al. (39), who found elevated levels
of ferritin in HIV-infected individuals without correlation
with iron deficiency anemia. In this latter investigation, the
iron biomarker soluble transferrin receptor (sTfR) was the
best predictor of anemia in the HIV-infected participants,
and (sTfR) was also associated with a 6-fold increase in
the odds of anemia. Hassan et al. (41) concluded that
humoral, nonspecific immunity (phagocytic activity and
oxidative burst), and IL-6 are influenced in patients with iron
deficiency anemia. Other evidence also suggests that anemia
is associated with an increased risk of all-cause mortality and
tuberculosis among HIV-infected individuals, regardless of
anemia type, and the magnitude of the risk is higher with
more severe anemia (38).
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PD and dehydration are also associated with undernutri-
tion and a weakened immune system, including that caused
by HIV infection in children (42, 43). There is low certainty
on the use of antibiotic therapy (e.g. nitazoxanide) in children
with PD (44, 45). Adequately powered trials are needed to
assess the effect of micronutrients and nitazoxanide, as
well as other interventions, for the treatment of diarrhea
in HIV-infected and -exposed children. Currently, there is
emerging interest in nutrient-based interventions, including
the use of pre- and probiotics, as a novel strategy to manage
gut microbiome imbalance and gut-mucosal impairment
and to reduce immune activation, thereby potentially
forestalling the outcome of PD in children (44, 45).
Probiotics may also improve the resident gut microbiome
in adults with HIV (46). Even though the beneficial effects
of probiotics are quite promising, their effectiveness in
the intestinal mucosa are strain dependent, and not all
interventions are equally effective (45, 47). Prebiotics
are also used to modulate resident gut homeostasis and
selectively promote the growth of beneficial bacterial species
(48). Studies showing the effects of pre- and probiotics
on gut microbiota, inflammation, and other health
conditions in HIV-infected individuals are presented in
Table 1.
TABLE 1 Effect of prebiotics and probiotics on HIV infection
Study/country/duration Objective Study design
Sample characteristics
/ size Summary of findings
d’Ettorre, et al. (49)
Italy48 weeks
Investigate the potential
benefits of 48 wk of
probiotics supplementation
on immune function and on
immune activation status







reduced the levels of immune activation on
CD4 T-lymphocytes. Supplementing cART
with probiotics may improve GI tract
immunity and thereby mitigate
inflammatory sequelae, ultimately
improving prognosis
Yang et al. (50)
USA
90 d
Study the safety and immune








Bacillus coagulans probiotic preparation was
safe and well tolerated in persons with
chronic HIV-1 infection on suppressive cART
and increased the percentage of CD4+ T
compared to control. There was also a
possible benefit of this probiotic for residual
inflammation
Klatt et al. (46)
USA











The symbiotic, prebiotic, and probiotic
supplementation of ARV treatment
enhanced GI immune function (thereby
mitigating inflammatory sequelae),
increased reconstitution of colonic CD4+
T-cells, and reduced fibrosis of lymphoid
follicles in the colon
Serrano-Villar et al. (51)
Spain
6 wk




of disease progression after
dietary supplementation
with prebiotics




(HIV–) N = 44
Significant declines in indirect markers of
bacterial translocation and T-cell activation.
Increases in the abundance of
Faecalibacterium and Lachnospira strongly
correlated with moderate but significant
increases of butyrate production and
amelioration of the inflammatory
biomarkers soluble CD14 and
high-sensitivity C-reactive protein, especially
among VU















Dietary supplementation with a prebiotic
oligosaccharide mixture significantly results
in improvement of the gut microbiota
composition, reduction of sCD14, CD4+
T-cell activation (CD25), and improved NK
cell activity in HAART-naive HIV-infected
individuals






immunity in HIV infection
Review HIV-infected patients
N = 24
There was no indication that critically ill and
high-risk participants taking probiotics were
more likely to experience adverse events
than control participants with the same
health status
ARV, antiretroviral therapy; CD25, IL-2 receptor α chain; cART, combination antiretroviral therapy; CD4+, cluster of differentiation 4+; GI, gastro-intestinal; HAART, highly active
antiretroviral therapy; NK, natural killer; RCT, randomized control trial; sCD14, soluble cluster of differentiation 14; SIV, Simian immunodeficiency virus; TCID, tissue culture infective
dose.
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In a multicountry analysis of the impact of diarrhea
among several cohorts of HIV-infected children followed
from birth until the age of 24 mo, Checkley et al. (52) found
that the adjusted odds of stunting increased by 1.13 for every
5 episodes of diarrhea (95% CI: 1.07–1.19) and by 1.16 for
every 5% unit increase in longitudinal growth (95% CI: 1.07–
1.25). This confirmed an earlier study by Richard et al. (53),
in which diarrhea was associated with a small but measurable
decrease in linear growth over the long term.
The relation between HIV infection, nutrition, and the
immune system in infants and children is complex. These
conditions interact and can create a vicious circle leading to
poor health outcomes.
Nutritional status of HIV-infected infants and children
Abnormalities in weight and height are adverse nutritional
outcomes in children living with HIV (11, 54) and can
be considered markers of disease progression and signif-
icant contributors to morbidity and mortality (54). Poor
nutritional status of HIV-infected children, including those
who have already started ART, is closely associated with
increased risk of premature death. HIV-infected children
who are significantly underweight are much more likely to
die than HIV-infected children who are not malnourished
(55). Similar findings have been described in adults living
with HIV, including adults receiving ART (56).
Causes of growth impairment in HIV-infected children
may include reduced food intake and opportunistic infec-
tions that affect food consumption, nutrient absorption, and
metabolism leading to weight loss (8). HIV-infected children
remain at high risk of wasting and stunting within the first
5 y of follow-up treatment (11). ART has been shown to have
a positive effect on weight and, to a lesser extent, on growth
(57). However, Sofeu et al. (11) concluded that a mother or
child’s HIV infection status affects the child’s growth during
the first years of life, regardless of the availability of ART. In
a study by Feucht et al. (58), weight improved in the first
12 mo, and height improved more slowly over the entire 5-y
follow-up period in HIV-infected children initiated on ART
before the age of 5 y. The overall prevalence of undernutrition
among HIV-infected children in a hospital in Cameroon
was 68.7%. In this study, 63.6% were stunted [height-for-
age z-score (HAZ) < −2], 37.8% were underweight [weight-
for-age z-score (WAZ) < −2], and 18.4% exhibited wasting
WHZ < −2 (23). In another investigation by Poda et al.
(24), the prevalence of underweight, stunting, and wasting
in HIV-infected children aged <5 y was 77%, 65%, and 63%,
respectively. Akintan et al. (59) concluded that HIV-infected
children are 3 times more wasted, stunted, and underweight
than HIV-uninfected children.
Associations between abnormal body fat distribution and
pediatric HIV disease have been established in various
studies (60–62). HIV infection itself is a factor that causes
lipodystrophy syndrome in children who are being treated
with antiretroviral medications (63) and could refer to
abnormal fat accumulation (lipohypertrophy) or localized
loss of fatty tissue (lipoatrophy) (64).
Micronutrient deficiencies are also widely prevalent
in HIV-infected children receiving highly active ART
(HAART), irrespective of social class (65). In a study of HIV-
infected children by Anyabolu et al. (65), the prevalence of
zinc, selenium, and vitamin C deficiency were 77.1%, 71.4%,
and 70.0%, respectively, compared with 44.3%, 18.6%, and
15.7% in HIV-negative controls.
Given the relation between HIV, nutrition, growth fal-
tering, and survival of children living with HIV, it becomes
crucial that nutritional assessment and support should be an
integral part of the care plan of HIV-infected children. Proper
dietary support to meet nutritional needs and ART initiation
are essential before irreversible stunting occurs. New inter-
vention studies aimed to optimize the required nutritional
support to attain growth normalization are needed.
Problems affecting feeding practices among
HIV-infected infants and children
In poor settings with limited resources, knowledge, per-
ceptions, and practices of HIV-positive mothers concerning
the feeding of their infants are inadequate (66, 67). This
implies that a sizeable percentage of infants are at increased
risk of acquiring HIV through inappropriate feeding. How-
ever, Mnyani et al. (68) reported higher knowledge scores
regarding infant feeding practices during HIV infection
among women with HIV than women without HIV. In HIV
infection, cultural factors and functional social support are
important influences on safe infant feeding choices (68, 69).
Fear of the mother of HIV transmission to the child has been
reported by Remmert et al. (70) as a common reason for not
breastfeeding their exposed-uninfected infants. This could
be the result of misleading information about the safety of
breastfeeding and the risks associated with formula feeding.
In a large survey involving mothers and their infants in
99 primary health care (PHC) clinics in South Africa, about
a quarter of them did not receive breastfeeding advice at the
clinic (71). In a meta-analysis of 18 studies in Ethiopia, the
national pooled prevalence of exclusive breastfeeding and
mixed feeding practices among HIV-positive mothers was
63.43% and 23.11%, respectively (72). High rates of formula
feeding were also reported among women with HIV (73).
According to the WHO guidelines (74), it is recom-
mended (with substantial evidence) that mothers living
with HIV and fully supported for ART, should exclusively
breastfeed their infants for the first 6 mo. Furthermore,
breastfeeding with complementary feeding may continue
≤2 y or beyond. Exclusive breastfeeding of HIV-exposed
infants in the first 6 mo of life has been reported to be
associated with reduced mortality over the first year of life
compared with mixed feeding and replacement feeding (74).
Oral diseases are also common problems in HIV-positive
children (75). Oral candidiasis is the most frequently found
HIV-related oral manifestation which can affect infants’
feeding practices (67, 68). Dental diseases also affect HIV-
infected children. The quality of life and daily activities of
HIV-infected children affected by oral and dental diseases
result in eating difficulties and other functional limitations
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(76). A recent study in HIV-infected patients has also found
that oral candidiasis might be a useful marker for the
evaluation of immune status in patients with HIV/AIDS (77).
An association between CD4+ count and the presence of
oral lesions has been demonstrated in the literature (78, 79).
However, Yengopal et al. (80) found no substantial evidence
of a significant association between the presence of dental
caries among HIV-positive children and CD4 counts and
viral load, meaning that a more robust trial to gain new
scientific evidence is needed to ascertain the linkage between
oral diseases and CD4+ count in HIV-infected children.
All this information indicates that infants and children
remain at risk of HIV complications from inappropriate feed-
ing practices. Within this context, breastfeeding, particularly
exclusive breastfeeding during the first 6 mo of life, plays
an important nutritional role in the management of HIV-
infected infants and children.
ART and nutrition
ART treatment has significantly improved life expectancy,
health care, and survival for people living with HIV in
the past 2 decades (81). It has also substantially decreased
mortality and morbidity of the pediatric HIV-infected popu-
lation (82). However, despite evidence of the potential benefit
of ART use in HIV-related survival, severe wasting (WHZ
< –3) appears to be a strong independent predictor of
survival in HIV-infected children receiving ART (83). In a
study on the impact of HAART on the nutritional status
of HIV-infected children, moderate and severe underweight
were both independent predictors of a positive shift in
nutritional status (WAZ and WHZ) after 24 mo of follow-
up (84). Older studies have demonstrated severe wasting to
be associated with death in children after ART initiation
(55, 85, 86). New studies have shown increased risk of
mortality in HIV-infected children who are underweight at
the initiation of ART (87, 88). In a previous study, ART initi-
ation resulted in improved weight and height gains among
severely malnourished children (82). Still, the observed
increases were not enough to reach optimal growth when
compared with nonmalnourished children. ART initiation
and nutritional supplementation at an early age have been
found to be a significant factor for improvement in growth
outcomes and better nutritional status in the long term
(89). This observation has been confirmed by a number of
studies in children indicating that the earlier the treatment,
the better the nutritional response in weight and height
(37, 90). Additional randomized control trials (RCTs) are
needed to assist in determining the optimal timing of ART
and nutritional intervention in HIV-infected malnourished
infants and children.
Prevention of MTCT of HIV
MTCT of HIV occurs when HIV is transmitted from an
HIV-infected mother to her infant during pregnancy, labor,
delivery, or through breastfeeding (91). An HIV-infected
pregnant woman has a 15–45% likelihood of transmitting
the virus to her child in the absence of ART intervention;
however, with ART, the risk can be reduced to <5% (92).
Placental macrophages, also known as Hofbauer cells, found
within the chorionic villi of the human placenta, are vital
mediators that prevent in utero transmission of HIV-1 (93).
These cells have been shown to have a phenotype associated
with regulatory and anti-inflammatory functions (94). They
possess intrinsic adaptations that expedite the isolation of
HIV-1 in intracellular compartments allowing access of HIV-
1-specific antibodies and antiretroviral drug entry in utero,
thereby offsetting MTCT (93).
Several studies have reported strong associations of
some pathogens such as human cytomegalovirus (HCMV),
viremia (95), malaria (96), and tuberculosis (97) with the
in utero transmission of HIV-1, thereby contributing to the
high incidence of MTCT. Maternal placenta HCMV infection
facilitates inflammation, chronic villitis, and trophoblast
damage, providing potential HIV-1 access into the primary
receptor (CD4) and coreceptor (CCR5) target cells (95).
Choices on whether or not HIV-infected mothers ought to
breastfeed their babies are based on comparing the potential
risks of infants acquiring HIV through breastfeeding with
the elevated threat of loss of life from malnutrition, diarrhea,
and pneumonia if the infants are not exclusively breastfed.
Accumulating evidence has shown that giving antiretroviral
medicines to the mother or the infant significantly reduces
the risk of HIV transmission through breastfeeding (98).
A study by Chan et al. (99) on HIV detection among
42 breastfeeding Kenyan women showed that at 6–14 wk
postpartum, 21.4% had HIV RNA detected in plasma and
14.3% in breast milk. However, when adjusting the time
of beginning ART, earlier ART initiation in pregnancy was
significantly associated with plasma suppression of the virus.
The WHO therefore recommends that mothers living
with HIV should breastfeed for ≥12 mo and may continue
breastfeeding for ≤24 mo or longer (similar to the general
population) while being fully supported for ART adherence
(91). Mothers known to be HIV infected should be provided
with lifelong ART or antiretroviral prophylaxis to reduce
HIV transmission through breastfeeding. The risk of MTCT
of HIV can be significantly reduced through the provision
of maternal ART as early as possible during pregnancy or
preconception (91).
In summary, the available information indicates that the
best prevention strategy and management of HIV-infected
mothers to lower the risk of HIV transmission from mother
to child include the early use of antiretroviral agents and op-
timum nutritional support for pregnant and lactating women
as well as their children. Other management strategies
include rapid HIV testing, monitoring, and support for an-
tiretroviral adherence as well as counseling on infant feeding.
Nutrition as an Adjunct Therapy
Dietary formulations for feeding severely malnourished
infants
The management of SAM in children can be divided
into 2 phases: stabilization and rehabilitation (100). In the
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stabilization phase, F-75, a starter, low protein (0.9 g per
100 mL) milk-based therapeutic diet with relatively low
energy [75 kcal (314 kJ) (101)] is administered for a
period of 2 to 7 d. Once the child is stabilized, ready-to-
use therapeutic foods (RUTFs) can then be administered
during the rehabilitation phase (75, 78). RUTFs are semisolid
products (which include milk powder, sugar, peanut butter,
vegetable oil, vitamins, and minerals) developed initially as a
home-based follow-up treatment, usually made according to
a standard, energy-rich formula defined by the WHO (102).
Treatment of SAM in infants for 6 mo to 1 y in clinics has
not been beneficial, especially in rural areas; hence the use
of home-based therapies has been found to be better (103).
Home-based treatment can be either food prepared by a
caregiver (such as flour porridge or energy- and nutrient-
dense locally available foods), or RUTF provided by a clinic
(103). The WHO recommends the same therapeutic feeding
approaches in HIV-infected children aged under 5 y with
SAM versus HIV-uninfected under-5 children with SAM
(104). However, the metabolic and nutrient needs of HIV-
infected children, in whom persistent anorexia is frequent,
should be better defined.
RUTF has transformed the treatment of SAM, providing
foods that are safe to use at home and ensure rapid weight
gain (105). Low acceptability has been found to occur
for standard RUTF products (106), most likely because of
the high milk content of the standard RUTF formulation
that makes it expensive for sustainable use in resource-
poor settings (107). However, progress has been made in
terms of increasing acceptability of RUTF by using locally
grown ingredients (108). Irena et al. (109) reported that the
removal of milk powder and the inclusion of locally available
grains and pulses could reduce the cost of ingredients by
about a third. Innovative RUTF formulations with reduced
milk protein or no milk protein have been evaluated in
different study settings (107, 109–111). Results indicate that
alternative RUTFs can be effective in managing SAM in
children. However, there is no consistency regarding the
reported superiority when using different new formulations
as compared to the standard RUTF. For example, the WHO
is currently reviewing the efficacy and safety of new RUTF
formulations (containing alternative sources of nondairy
protein or <50% of proteins coming from milk) for treating
infants and children aged 6 mo or older with uncomplicated
SAM and appetite (112). The primary reason is to reduce the
production cost of these formulations and increase coverage
by replacing milk (the most expensive ingredient) with other
sources of protein.
A study by Sunguya et al. (113), among HIV-positive
children in a clinical setting in Dar Es Salaam, Tanza-
nia, showed that provision of a RUTF formula, made of
plumpy’nut, for ≥4 mo did not increase the average weight
gain in HIV-infected children, especially when given ART.
Moreover, an RCT of children with SAM, aged 6–59 mo,
revealed that the standard RUTF was not superior to locally
produced fish-based RUTF on its effect on weight gain
(106). One trial reported a weight gain of 3.45 g/kg/d in
a group of children receiving indigenously prepared RUTF
over 8 wk compared with 2.38 g/kg/d in the group receiving
standard nutrition therapy during the same period (111).
When comparing recovery in children aged <5 y, based
on weight gain of ≥15% (109, 114), or midupper arm
circumference (MUAC) of >12.4 cm without edema (115),
there was no significant difference between standard RUTF
versus RUTF using alternative formulations. In other studies,
there was no significant difference between standard RUTF
and alternative diets when measuring improvement after
16 wk (116) or 6 mo of interventions (111). In a meta-analysis
by Schoonees et al. (103), comparing standard RUTFs with
different formulations for children aged 6 mo to 5 y, the
evidence did not favor a particular formulation, except for
relapse, which is reduced with standard RUTF. The com-
parison between standard RUTFs and other experimental
formulas are depicted in Table 2. It can be observed that
experimentally modified food formulations equally improve
survival and nutritional status of children with SAM when
compared to standard RUTFs, and in some cases, the new
experimental diets were superior to the standard.
There is a dearth of information on the effect of standard
RUTF on mortality, especially in the context of HIV-
infected infants (97). It is, therefore, important to assess the
effectiveness and cost analysis of formulations of ready-to-
use foods for the nutritional management of SAM in HIV-
infected infants and children using properly designed RCTs
with standardized outcome measures that include diarrhea
and other complications. It is strongly recommended to
provide appropriate feeding protocols and nutrition support
for severely malnourished HIV-infected infants, especially in
the case of severe diarrhea, which is often associated with
high mortality (90).
Micronutrient supplementation
Micronutrient deficiencies are common among patients with
HIV (117). Trials testing the effectiveness and safety of vita-
min A in HIV-positive children in Africa found a beneficial
effect on mortality and growth (118–120). In a meta-analysis
by Irlam et al. (121), the overall mortality rate of 267 HIV-
infected children receiving vitamin A supplementation was
approximately halved. The WHO recommends high doses
of vitamin A supplementation for HIV-infected infants and
children aged 6–59 mo, in resource-poor settings where
the prevalence of vitamin A deficiency (serum retinol
0.70 μmol/L or lower) is 20% or higher (122).
In a cross-sectional study involving children with peri-
natally acquired HIV on stable ART for ≥6 mo, higher
plasma selenium concentrations were associated with lower
systemic inflammation and more elevated gut integrity
markers (123). The plasma selenium concentration was
associated with a higher proportion of T-cell activation (124)
whereas zinc supplementation, in a pilot study, increased
circulating zinc concentrations and modulated biomarkers
associated with clinical comorbidities in HIV-positive adults
(125). In a randomized, double-blind, placebo-controlled
trial in infants (aged 6 wk, baseline) born to HIV-positive
mothers in Tanzania, Liu et al. (126) found that daily





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 Fabusoro and Mejia
multivitamin supplementation (vitamin B complex, C and
E) improved the children’s hematologic status after 24 mo
of intervention compared to a placebo group. However, a
contrasting effect of multivitamin supplementation and zinc
on iron status of infants was observed in a study by Carter
et al. (131). This investigation revealed an association of
multivitamins with improved iron status in infants, whereas
zinc supplementation resulted in an increased risk of iron
deficiency, though there was no association with increased
risk of anemia in the long term.
Vitamin D deficiency (VDD) is prevalent among HIV
patients (132, 133). An association between low concentra-
tions of vitamin D and the progression of HIV disease and
the immune system has been ascertained in various studies
(134–136). In a retrospective cohort investigation among
HIV-infected untreated adults, VDD was associated with an
increased time to decline in CD4 cell count to <350 cells/μL.
In a cross-sectional study by Mirza et al. (137) assessing
the correlation between vitamin D status in HIV-infected
children and the duration and severity of their infection,
higher CD4 counts were associated with higher vitamin D
concentrations. Lower bone mineral density (BMD) has been
common in HIV-infected children (138); however, a high
dose of vitamin D and calcium supplementation attenuate the
loss of BMD (139, 140).
In general, micronutrient supplementation seems positive
in infants and children with HIV. However, further RCTs are
required to assess the effect of micronutrient supplements to
determine the long-term impact and optimal composition
and dosing of single and multiple micronutrient supplements
in infants and children infected with HIV.
Conclusions
Infants and children infected with HIV deserve special
attention because of increased nutrient needs for normal
growth and development. The prevention of MTCT remains
the best measure against HIV infection. However, despite
global policies on lifelong ART amongst pregnant women
to prevent or eliminate MTCT (141), adherence to maternal
ART for ≥18 mo postpartum is low and remains a crucial
challenge in resource-poor settings (142–144). The WHO
guidelines on ART timing of administration for pregnant and
breastfeeding HIV-positive women (145) should also include
effective strategies to improve adherence to ART treatment.
There is a paucity of evidence on the effect of standard
RUTF and other dietary formulations on mortality (103),
especially in the context of HIV in infants. It is crucial to
design more pragmatic RCTs to be able to ascertain the
effectiveness of low-cost RUTFs and other formulations with
standardized outcome measures such as diarrhea, anemia,
and other complications of HIV in infants and children with
SAM.
The initiation of ART should be immediate or within days
of HIV diagnosis. Unfortunately, only 43% of all children
living with HIV have access to ARV treatment (146). The
WHO recommends early testing and ART initiation for
HIV-infected children to reduce HIV-related mortality and
morbidity (5). In addition, proper nutritional assessment,
management, and support should be an integral part of the
care plan to avoid irreversible consequences of undernu-
trition. The positive role of breastfeeding is also evident,
particularly in the first 6 mo of life.
There are conflicting reports on the effectiveness of
micronutrient supplementations in the survival of children
living with HIV. There are no evidence-based guidelines on
the types and dosage of micronutrient supplements in the
context of HIV-infected children. Therefore, micronutrient
supplement studies are needed to determine the appro-
priate dosage to build the evidence base for the manage-
ment of HIV-infected children, especially when SAM is
present.
The primary cause of persistent intestinal inflammation
has been linked to undernutrition and dysbiosis of the gut
microbiome with PD as some of the major consequences
(30–32, 147). The WHO guidelines on the management
of diarrhea in HIV-infected infants and children stipulates
the use of vitamin A supplementation as a prevention
strategy, whereas zinc supplementation, low-osmolarity oral
rehydration solution (ORS), and daily micronutrients have
been recommended as treatment (148). There is emerging
interest in probiotic supplementation as a novel strategy to
manage dysbiosis and gut-mucosal impairment to reduce
immune activation, thereby potentially forestalling or en-
hancing the outcome of PD in children (44, 45). However, the
mechanisms by which probiotics exert their effects on the gut
microbiome still remain unclear, especially in HIV-infected
children. There is a need for adequately powered trials to
assess such effects, and this could be a novel intervention
strategy in the nutritional management of PD in HIV-
infected infants and children. As discussed here, the WHO
and other guidelines on HIV in infants and children need to
be reviewed owing to recent advances in the field of nutrition
in the context of HIV.
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